Table 2 Concomitant drugs
Drugs | Baseline (n = 204) | Week 12 (n = 204) |
|---|---|---|
Antidiabetic drug | 140 (68.6) | 138 (67.7) |
Sulfonylurea | 114 (55.9) | 113 (55.4) |
α-Glucosidase inhibitor | 19 (9.3) | 18 (8.8) |
Biguanide | 47 (23.0) | 49 (24.0) |
DPP-4 inhibitor | 8 (3.9) | 7 (3.4) |
Glinide | 3 (1.5) | 3 (1.5) |
Thiazolidinedione | 10 (4.9) | 10 (4.9) |
Other | 1 (0.5) | 0 (0.0) |
Antihypertensive drug | 121 (59.3) | 123 (60.3) |
Diuretic drug | 22 (10.8) | 20 (9.8) |
Calcium channel blocker | 75 (36.8) | 77 (37.8) |
ACE inhibitor | 9 (4.4) | 8 (3.9) |
Angiotensin II receptor blocker | 95 (46.6) | 98 (48.0) |
Direct renin inhibitor | 0 (0.0) | 0 (0.0) |
α-blocker | 0 (0.0) | 0 (0.0) |
β-blocker | 17 (8.3) | 18 (8.8) |
α1β-blocker | 4 (2.0) | 5 (2.5) |
α2 receptor agonist | 1 (0.5) | 1 (0.5) |
Other | 2 (1.0) | 2 (1.0) |
Lipid-lowering agent | 117 (57.4) | 118 (57.8) |
Statin | 103 (50.5) | 102 (50.0) |
Fibrate | 12 (5.9) | 12 (5.9) |
Ezetimibe | 6 (2.9) | 8 (3.9) |
Probucol | 0 (0.0) | 0 (0.0) |
EPA | 0 (0.0) | 0 (0.0) |
Resin | 0 (0.0) | 0 (0.0) |
Other | 4 (2.0) | 4 (2.0) |